A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia

Human Psychopharmacology

Volumn 19, Issue SUPPL. 1, 2004, Pages

  Vitton, Olivier ^a   Gendreau, Michael ^a   Gendreau, Judy ^a   Kranzler, Jay ^a   Rao, Srinivas G ^a  

^a Cypress Bioscience Inc   (United States)

Author keywords

Antidepressants; Fibromyalgia syndrome; Milnacipran; Pain

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIDEPRESSANT AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; MILNACIPRAN; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADRENERGIC TRANSMISSION; ADULT; AGED; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; GASTROINTESTINAL DISEASE; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERTENSION; LETHARGY; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SWEAT GLAND DISEASE; SYMPTOM; TACHYCARDIA; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 6344231258     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.622     Document Type: Article

References (25)

1. Arnold LM, Keck PE, Jr, Welge JA. 2000. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 41: 104-113.
2. Beck AT, Ward CH, Mendelson M. 1961. An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571.
3. Briley M, Prost JF, Moret C. 1996. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 11(Suppl. 4): 9-14.
4. Burckhardt CS, Clark SR, Bennett RM. 1991. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18 728-733.
5. Crofford LJ, Clauw DJ. 2002. Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum 46: 1136-1138.
6. Fishbain D. 2000. Evidence-based data on pain relief with antidepressants. Ann Med 32: 305-316.
7. Gracely RH, Kwilosz DM. 1988. The descriptor differential scale: applying psychophysical principles to clinical pain assessment. Pain 35: 279-288.
8. Hudson JI, Pope HG, Jr. 1996. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 22: 285-303.
9. Leventhal LJ. 1999. Management of fibromyalgia. Ann Intern Med 131: 850-858.
10. McCain GA. 1994. Fibromyalgia and myofacial pain. In Textbook of Pain, 3rd edn, Wall PD, Melzack R (eds). Churchill Livingstone: Edinburgh; 475-493.
11. McGahuey CA, Gelenberg AJ, Laukes CA, et al. 2000. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26: 25-40.
12. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. 1985. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethylaminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24: 1211-1219.
13. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. 2000. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 15: 659-666.
14. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. 1997. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99-108.
15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl. 20): 22-33.
16. Staud R. 2004. Fibromyalgia pain: do we know the source? Curr Opin Rheumatol 16: 157-163.
17. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. 2001. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain 91: 165-175.
18. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. 2002. Patient non-compliance with paper diaries. Br Med J 324 1193-1194.
19. Van Amerongen AP, Ferrey G, Tournoux A. 2002. A randomised, double-blind comparison of milnacipran and imipramine in the treatment of depression. J Affect Disord 72: 21-31.
20. Ware JE, Jr, Sherbourne CD. 1992. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483.
21. Wessely S, Nimnuan C, Sharpe M. 1999. Functional somatic syndromes: one or many? Lancet 354: 936-939.
22. White KP, Harth M. 2001. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 5: 320-329.
23. Wolfe F, Smythe HA, Yunus MB, et al. 1990. The American College of Rheumatology 1990. Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 33: 160-172.
24. Wolfe F, Zhao S, Lane N. 2000. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 43: 378-385.
25. Yunus MB. 1992. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. J Rheumatol 19: 846-850.